Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 403 | 77 | 324 |
| Samples | 371 | 75 | 294 |
| Peptides | 230 | 39 | 210 |
Function
PSG2 · Pregnancy specific beta-1-glycoprotein 2
The human pregnancy-specific glycoproteins (PSGs) are a family of proteins that are synthesized in large amounts by placental trophoblasts and released into the maternal circulation during pregnancy. Molecular cloning and analysis of several PSG genes has indicated that the PSGs form a subgroup of the carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily of genes. Members of the CEA family consist of a single N domain, with structural similarity to the immunoglobulin variable domains, followed by a variable number of immunoglobulin constant-like A and/or B domains. Most PSGs have an arg-gly-asp (RGD) motif, which has been shown to function as an adhesion recognition signal for several integrins, in the N-terminal domain (summary by Teglund et al., 1994 [PubMed 7851896]). For additional general information about the PSG gene family, see PSG1 (MIM 176390).[supplied by OMIM, Oct 2009].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000406487 | P11465 | 403 | 230 |
Gene Properties
Recurrent Mutations
All 230 amino-acid changes on canonical ENST00000406487 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PSG2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PSG2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 5/133 4% |
| Melanoma | 6/210 3% | 61/1899 3% |
| Endometrial Carcinoma | 6/42 14% | 14/612 2% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 18/810 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 7/304 2% | 26/1390 2% |
| Colorectal Carcinoma | 8/143 6% | 34/3239 1% |
| Bladder Carcinoma | 0/58 0% | 12/956 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Cervical Carcinoma | 2/35 6% | 3/422 1% |
| Other Solid Cancers | 3/94 3% | 14/1515 1% |
| Rhabdomyosarcoma | 2/33 6% | 0/171 0% |
| Hepatocellular Carcinoma | 2/46 4% | 19/2210 1% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Esophageal Carcinoma | 3/23 13% | 4/769 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 6/752 1% |
| Gastric Carcinoma | 0/74 0% | 14/1809 1% |
| Other Sarcomas | 3/69 4% | 2/699 0% |
| Prostate Carcinoma | 2/13 15% | 10/2105 0% |
| Neuroendocrine Tumour | 1/154 1% | 3/577 1% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 11/2550 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Ovarian Carcinoma | 2/109 2% | 3/998 0% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 6/1592 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 4/2534 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
Mutation Distribution
Where PSG2 is mutated · all tissues, split by cell line vs tissue
How many mutations in PSG2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 3 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 403 mutations in PSG2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|